WO2015156581A1 - 안정성이 개선된 프레가발린을 함유하는 약제학적 조성물 및 이의 제조방법 - Google Patents
안정성이 개선된 프레가발린을 함유하는 약제학적 조성물 및 이의 제조방법 Download PDFInfo
- Publication number
- WO2015156581A1 WO2015156581A1 PCT/KR2015/003475 KR2015003475W WO2015156581A1 WO 2015156581 A1 WO2015156581 A1 WO 2015156581A1 KR 2015003475 W KR2015003475 W KR 2015003475W WO 2015156581 A1 WO2015156581 A1 WO 2015156581A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sustained
- pregabalin
- pharmaceutical composition
- improved stability
- coating
- Prior art date
Links
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 title claims abstract description 116
- 229960001233 pregabalin Drugs 0.000 title claims abstract description 110
- 238000000034 method Methods 0.000 title claims abstract description 37
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 35
- 239000011248 coating agent Substances 0.000 claims abstract description 92
- 238000000576 coating method Methods 0.000 claims abstract description 78
- 239000012730 sustained-release form Substances 0.000 claims abstract description 72
- 238000013268 sustained release Methods 0.000 claims abstract description 69
- 239000000203 mixture Substances 0.000 claims abstract description 68
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 58
- 238000009472 formulation Methods 0.000 claims abstract description 39
- 239000004014 plasticizer Substances 0.000 claims abstract description 14
- 235000000346 sugar Nutrition 0.000 claims abstract description 12
- 150000003839 salts Chemical class 0.000 claims abstract description 11
- 150000008163 sugars Chemical class 0.000 claims abstract description 4
- 229940079593 drug Drugs 0.000 claims description 59
- 239000003814 drug Substances 0.000 claims description 59
- 239000003795 chemical substances by application Substances 0.000 claims description 36
- 239000004480 active ingredient Substances 0.000 claims description 28
- 238000004519 manufacturing process Methods 0.000 claims description 18
- 230000008961 swelling Effects 0.000 claims description 17
- 239000011159 matrix material Substances 0.000 claims description 16
- 239000002202 Polyethylene glycol Substances 0.000 claims description 15
- 238000002156 mixing Methods 0.000 claims description 15
- 229920001223 polyethylene glycol Polymers 0.000 claims description 14
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 13
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 13
- 239000002245 particle Substances 0.000 claims description 13
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 11
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 11
- -1 manniol Chemical compound 0.000 claims description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 9
- 229930006000 Sucrose Natural products 0.000 claims description 9
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 9
- 239000005720 sucrose Substances 0.000 claims description 9
- 229920002554 vinyl polymer Polymers 0.000 claims description 9
- 238000005507 spraying Methods 0.000 claims description 8
- 239000000654 additive Substances 0.000 claims description 7
- 150000001720 carbohydrates Chemical class 0.000 claims description 7
- 239000000314 lubricant Substances 0.000 claims description 7
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical group [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 6
- 239000004376 Sucralose Substances 0.000 claims description 6
- 229920000578 graft copolymer Polymers 0.000 claims description 6
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 6
- 235000019408 sucralose Nutrition 0.000 claims description 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 5
- 229920002125 Sokalan® Polymers 0.000 claims description 5
- 239000011230 binding agent Substances 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 5
- 239000007884 disintegrant Substances 0.000 claims description 5
- 239000012453 solvate Substances 0.000 claims description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 4
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 4
- 229960001631 carbomer Drugs 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 229960000502 poloxamer Drugs 0.000 claims description 4
- 229920001983 poloxamer Polymers 0.000 claims description 4
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims description 4
- 235000013772 propylene glycol Nutrition 0.000 claims description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 3
- 239000004348 Glyceryl diacetate Substances 0.000 claims description 2
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 2
- 235000019443 glyceryl diacetate Nutrition 0.000 claims description 2
- 239000001087 glyceryl triacetate Substances 0.000 claims description 2
- 235000013773 glyceryl triacetate Nutrition 0.000 claims description 2
- 229960002622 triacetin Drugs 0.000 claims description 2
- 239000001069 triethyl citrate Substances 0.000 claims description 2
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 2
- 235000013769 triethyl citrate Nutrition 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 8
- 238000012377 drug delivery Methods 0.000 abstract description 6
- 208000001640 Fibromyalgia Diseases 0.000 abstract description 4
- 206010015037 epilepsy Diseases 0.000 abstract description 4
- 208000004296 neuralgia Diseases 0.000 abstract description 4
- 208000021722 neuropathic pain Diseases 0.000 abstract description 4
- 208000020016 psychiatric disease Diseases 0.000 abstract description 4
- 230000002265 prevention Effects 0.000 abstract description 2
- 238000002360 preparation method Methods 0.000 description 23
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 239000004372 Polyvinyl alcohol Substances 0.000 description 8
- 238000004090 dissolution Methods 0.000 description 8
- 230000002496 gastric effect Effects 0.000 description 8
- 229920002451 polyvinyl alcohol Polymers 0.000 description 8
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 8
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 7
- 239000008187 granular material Substances 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 description 6
- 238000010828 elution Methods 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 5
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 5
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 5
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 5
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 5
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 5
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 5
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 5
- 238000007667 floating Methods 0.000 description 5
- 238000005469 granulation Methods 0.000 description 5
- 230000003179 granulation Effects 0.000 description 5
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 5
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 5
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- 229920000609 methyl cellulose Polymers 0.000 description 5
- 235000010981 methylcellulose Nutrition 0.000 description 5
- 239000001923 methylcellulose Substances 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 229920002689 polyvinyl acetate Polymers 0.000 description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 239000004474 valine Substances 0.000 description 5
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 239000001856 Ethyl cellulose Substances 0.000 description 4
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 4
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 4
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 238000007922 dissolution test Methods 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 235000019325 ethyl cellulose Nutrition 0.000 description 4
- 229920001249 ethyl cellulose Polymers 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000011118 polyvinyl acetate Substances 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 3
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 238000009501 film coating Methods 0.000 description 3
- 239000007888 film coating Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 150000004677 hydrates Chemical class 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 229960001375 lactose Drugs 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 230000000704 physical effect Effects 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 2
- 239000004254 Ammonium phosphate Substances 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920001100 Polydextrose Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 2
- 229910000148 ammonium phosphate Inorganic materials 0.000 description 2
- 235000019289 ammonium phosphates Nutrition 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 2
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 229940014259 gelatin Drugs 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 2
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229960001021 lactose monohydrate Drugs 0.000 description 2
- 238000005461 lubrication Methods 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 235000013856 polydextrose Nutrition 0.000 description 2
- 239000001259 polydextrose Substances 0.000 description 2
- 229940035035 polydextrose Drugs 0.000 description 2
- 229920000193 polymethacrylate Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 239000004604 Blowing Agent Substances 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 235000013913 Ceratonia Nutrition 0.000 description 1
- 241001060815 Ceratonia Species 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 1
- 102000005915 GABA Receptors Human genes 0.000 description 1
- 108010005551 GABA Receptors Proteins 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940124277 aminobutyric acid Drugs 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 235000010407 ammonium alginate Nutrition 0.000 description 1
- 239000000728 ammonium alginate Substances 0.000 description 1
- KPGABFJTMYCRHJ-YZOKENDUSA-N ammonium alginate Chemical compound [NH4+].[NH4+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O KPGABFJTMYCRHJ-YZOKENDUSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000002216 antistatic agent Substances 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 235000010410 calcium alginate Nutrition 0.000 description 1
- 239000000648 calcium alginate Substances 0.000 description 1
- 229960002681 calcium alginate Drugs 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229940043431 ceratonia Drugs 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000002925 chemical effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 238000004581 coalescence Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000000748 compression moulding Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000007905 drug manufacturing Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940049654 glyceryl behenate Drugs 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 229910000271 hectorite Inorganic materials 0.000 description 1
- KWLMIXQRALPRBC-UHFFFAOYSA-L hectorite Chemical compound [Li+].[OH-].[OH-].[Na+].[Mg+2].O1[Si]2([O-])O[Si]1([O-])O[Si]([O-])(O1)O[Si]1([O-])O2 KWLMIXQRALPRBC-UHFFFAOYSA-L 0.000 description 1
- 239000001341 hydroxy propyl starch Substances 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 238000003402 intramolecular cyclocondensation reaction Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940009697 lyrica Drugs 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- XJRBAMWJDBPFIM-UHFFFAOYSA-N methyl vinyl ether Chemical compound COC=C XJRBAMWJDBPFIM-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000003955 neuronal function Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229910000275 saponite Inorganic materials 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- HRQDCDQDOPSGBR-UHFFFAOYSA-M sodium;octane-1-sulfonate Chemical compound [Na+].CCCCCCCCS([O-])(=O)=O HRQDCDQDOPSGBR-UHFFFAOYSA-M 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000002522 swelling effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000002966 varnish Substances 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 238000004078 waterproofing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
- A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
Definitions
- the present invention is a pharmaceutical composition comprising pregabalin and its pharmaceutically acceptable salts using a gastro-retentive drug delivery system that is secured, a preparation method thereof, and a sustained-release oral dosage form using the composition. It relates to a formulation for.
- Pregabalin is (S) -3- (Aminomethyl) -5-methylhexanoic acid (IUPAC Name; (3S-3- (Aminomethyl) -5-Methylhexanoic acid) .
- the molecular formula is C 8 Hi 7 N0 2 and molecular weight refers to compounds and derivatives thereof, known as 159.23, the chemical structure of 7 _-amino butyric acid ( "11 ⁇ 01 ⁇ 3 ⁇ -301 ( ⁇ ;.
- a GABA receptor does not bind to pregabalin
- pregabalin has been developed as a drug useful for treating various psychiatric disorders such as neuropathic pain, epilepsy, fibromyalgia, etc., and is marketed as an oral immediate release capsule product (trade name Lyrica capsule, Pfizer).
- Pregabalin is rapidly absorbed mainly from the upper gastrointestinal tract, reaching peak blood levels within 1.5 hours, and reaching a steady state within 24 to 48 hours after administration.
- the half-life is also about 6 hours in normal people. therefore,
- pregabalin is 150-600 mg / day, recommended twice or three times a day, starting at 75 mg and gradually increasing.
- Pregabalin is currently available only in immediate release formulations, not in modified release formulations.
- pregabalin gradually increases the dose of the drug while watching the reaction of the drug, and thus, the lack of medication due to the decrease in the patient's medication rate may have a completely different effect from the expected therapeutic effect. This can pose a significant risk in that the dosage can be increased unnecessarily.
- pregabalin is not absorbed uniformly in the gastrointestinal tract, making it difficult to work with general sustained release techniques.
- Pregabalin is in the upper gastrointestinal tract
- Gastric drug delivery systems are widely known as floating systems, expansion systems, bio-adheskm systems, and high density systems.
- Suspension system can keep the drug in the gastrointestinal tract for a long time by using the property of floating in gastric fluid through the lowering of the density of the preparation through the bubble generator.
- An inflation system is a system in which a drug is swelled using a swellable polymer to prevent passage of the pylorus through excretion of the stomach to allow the drug to remain in the stomach for a long time.
- Adsorption system is a system that adsorbs the drug on the gastric wall using sticky polymer to retain the drug in the stomach for a long time. But In the case of the adsorption system, due to the difference in the amount of mucus, consistency and metabolic rotation between people, it is difficult to be consistent, and may cause a problem that the drug attached to the gastric mucosa falls unexpectedly due to secretion of gastric juice or the like.
- the sedimentation system is a system that increases the density of the formulation and stays in the gastrointestinal tract as it is located in the gastrointestinal tract. However, it is practically limited to stay in the lower part of the gastric juice through high specific gravity.
- the floating system and the expansion system may be applied as appropriate technologies.
- Pregabalin is a type of ⁇ -amino acid, which causes intramolecular cyclization under normal storage conditions, resulting in PRG-Lactam (S-(+)-4). -Isobutyl-pyrrolidin-2-one). Because of the inevitable use of various excipients in sustained-release formulations, it is practically difficult to predict which excipients can lead to the formation of undesirable softeners such as PRG-lactams.
- Korean Patent Publication No. 2008-0059427 discloses polyvinylacetate used for the purpose of controlling release in order to keep pregabalin above.
- Formulations that swell to at least 9 mm when administered after a meal or before bedtime are provided using a mixture of polyvinylpyridone as a matrix and crosslinked polyvinylpyrrolidone as a swelling agent.
- Korean Patent Publication No. 201 1-0046360 is a sustained release formulation using a gastric retention system of pregabalin.
- Korean Patent Publication No. 2011-0123178 discloses swelling property of pregabalin. Swelling and floating gastric composition comprising a polymer and a gas generating material is provided. Korean Patent Laid-Open No. 2013-0023127 provides pregabalin with a gastric retention composition further comprising at least one of a swelling agent, a matrix former and a gas generator.
- the present inventors provide a composition having excellent formulation stability which improves the compatibility of pregabalin with an excipient.
- Compatibility with excipients refers to the intercompatibility between pregabalin and each excipient and refers to the effects of excipients on pregabalin, including the physical and chemical effects of the excipients as well as the ease of taking them.
- the composition having a stable formulation is improved in compatibility with various excipients for the purpose of controlling the release of the drug, and thus is a dosage form that can be used once a day for pregabalin for a long time in the stomach. At the same time it can be provided by securing the stability in the pharmaceutical composition.
- the present invention provides a composition having excellent formulation stability, which improves the compatibility between pregabalin and excipients, and aims to provide a sustained release formulation that can be administered once daily.
- the present invention is to provide a sustained-release pharmaceutical composition with improved stability prepared by forming a coating on the outer surface of the pregabalin-containing drug portion and mixed with a water release control unit comprising a sustained-release excipient do.
- an object of the present invention is to provide a method for producing a sustained-release pharmaceutical composition with improved stability.
- an object of the present invention is to provide a sustained-release pharmaceutical formulation with improved stability including the sustained-release pharmaceutical composition.
- Sustained release compositions and preparations comprising the same according to the present invention ensure stability and improve compatibility with excipients by introducing a coating portion containing sugars or derivatives and plasticizers on the outer surface of pregabalin having a less stable structure.
- the tok of conventional pregabalin This may result in improved treatment or prevention of various psychiatric disorders such as neuropathic pain, epilepsy, fibromyalgia, which have not been easily achieved.
- FIG. 1 is a SEM photograph of each particle (80Mesh ON, LOOMesh ON, 200Mesh ON, 200Mesh Pass) of the coating part including the main component of the pharmaceutical composition prepared in Preparation Example 1-3.
- Example 2 is an elution result obtained by the elution method of Experimental Example 1 to the tablet secured by the production method of Example 2-2.
- pregabalin has poor compatibility with various excipients, and therefore, stability is low when directly added various excipients. It was observed to lose and to increase the generation of lead substances. therefore,
- pregabalin In order to provide sustained-release formulation of pregabalin, securing the stability of pregabalin, the main ingredient, should be solved first.
- the stability of pregabalin is improved to improve the compatibility with excipients, and eventually the upper gastrointestinal tract.
- the present invention was completed by confirming that it is possible to achieve a dosage form that can be administered once daily for a long time in the present invention.
- the sustained-release pharmaceutical composition of the present invention is formulated by forming a coating portion on the outer surface of the drug portion containing the active ingredient, and then mixed with a drug release control portion containing a sustained-release excipient.
- a drug moiety comprising one or two or more active ingredients selected from the group consisting of pregabalin, pharmaceutically acceptable complexes thereof, salts thereof, solvates thereof and hydrates thereof;
- an improved sustained-release pharmaceutical composition comprising a drug release control unit comprising a pharmaceutically acceptable sustained-release excipient.
- Pregabalin is the active ingredient constituting the drug part (a) in the present invention
- the pregabalin in the present invention may be in free form or in any pharmaceutically acceptable form including pharmaceutically acceptable complexes, salts, solvates, hydrates and polymorphs.
- pharmaceutically acceptable salts means a substance which can be effectively used for a desired use without causing excessive toxicity, swelling, allergic reaction, etc. within the scope of the medical judgment.
- Pharmaceutically acceptable salts include salts derived from pharmaceutically acceptable inorganic acids, organic acids, or bases.
- suitable acids include hydrochloric acid, bromic acid, sulfuric acid, nitric acid, perchloric acid, fumaric acid, maleic acid, phosphoric acid, Glycolic acid, lactic acid, salicylic acid, succinic acid, toluene-P-sulfonic acid, tartaric acid, acetic acid, citric acid, methanesulfonic acid, formic acid, benzoic acid, malonic acid, naphthalene-2-sulfonic acid, and bansulfonic acid.
- Salts derived from suitable bases may include alkali metals such as sodium, potassium, alkaline earth metals such as magnesium, and ammonium and the like.
- Pregabalin can be easily prepared through various organic synthesis methods known in the art, or can be easily obtained through other commercial routes, for example, US Patent No. 5,563,175, US Patent No. 6,046,353, US Patent 5,840,956, U.S. Patent 5,637,767, U.S. Patent 5,629,447, U.S. Patent 5,616,793, and the like, but are not limited thereto.
- the amount of valine contained in the composition of the present invention are pharmacologically effective, and can be determined in consideration of the solubility of the daily dose, and a solvent that is exerted sufficiently layer not cause side effects, and from about 5 weight 0/0 to prepare the total composition 80 parts by weight to 0/0, preferably, may be included in an amount of from about 10% to 60% by weight.
- a typical content of pregabalin may be included in the range of about 50 mg to 900 mg, preferably 75 mg to 600 mg.
- the content of the pregabalin is less than 50mg, the concentration of pregabalin may not be sufficient to exert sufficient pharmacological effects, and if it exceeds 900mg, it may be difficult to control the sustained release due to the high concentration of pregabalin.
- Pregabalin-containing coating (a) in the present invention the stability of pregabalin
- a film-forming substance containing a saccharide or a derivative thereof in order to ensure the encapsulated particles.
- coating agent a film-forming substance containing a saccharide or a derivative thereof in order to ensure the encapsulated particles.
- particle in the present invention includes granules.
- the coating may improve the stability of the drug
- the drug release control layer It can also serve to control the emission in multiple layers.
- the coating part (b) formed on the outer surface of the drug part may include a saccharide or a derivative thereof as a coating agent.
- a coating agent is formed on the outer surface of the drug part by coating a coating agent including a sugar or a derivative thereof as a coating agent on the outer surface of the drug part as described above. Effectively block the interaction of valine with excipients.
- the sugar or derivative thereof is sucrose, manny, at least one selected from the group consisting of sucralose, more preferably sucrose or manny.
- the coating part may further include a plasticizer.
- a plasticizer When such a plasticizer is included, processability of the sugar or derivative thereof included in the coating agent may be properly performed as a coating material by excellent plasticity and adhesiveness peculiar to the plasticizer. It is more useful to improve the physical properties of the coating formed after the coating and to improve the physical properties of the coating, and to reduce the cracking or softness of the film that may occur when coating sugars or derivatives thereof.
- the plasticizer may be polyvinyl alcohol ⁇ polyethylene glycol graft copolymer, propylene glycol, diacetin, triacetin, triethyl citrate, diethyl phthalate, polyethylene glycol ( Polyethylene Glycol, Dibutyl Phthalate, Dibutyl Sebacate, Castor Oil, Acetylated Monoglyceride, and Talc It is preferable that it is 1 or more types.
- polyvinyl alcohol-polyethylene glycol graft copolymer is a water-soluble polymer having excellent flexibility and adhesion, and has a molecular structure. Since it is a copolymer of linear and flexible polyethylene glycol and polyvinyl alcohol, it can effectively act as a stabilizer between pregabalin raw materials, and adds processability and flexibility during coating. In particular, it is located evenly between pregabalin raw materials and enjoys compatibility problems with excipients, and buffers and lubricants during tableting, and due to the interaction with the excipients and friction, heat, pressure generated during tableting
- polyvinyl alcohol-polyethylene glycol graft copolymers examples include Kollicoat IR® (BASF) and the like.
- Saccharides or derivatives thereof is used as a coating portion coating formed on the drug unit exterior to 40 parts by weight on a dry weight basis% based on the total parts by weight of the coating 98 weight 0/0, preferably from 50 weight percent to 95 weight 0/0 may be included in, the plasticizer may comprise from 0 2 weight / weight 0-60 0/0, preferably from 5 weight 0 /. to 50 parts by weight 0 /. If the sugar content of the coating portion or derivative thereof is less than 50% by weight can not form a sufficient coating film, if more than 95% by weight when forming the coating portion of the sugar or derivative thereof, the flexibility or processability is lowered to form an appropriate coating film.
- the plasticizer is 2 parts by weight or 0 / less than 0, and a crack or the like coating formed can not give a proper flexibility and workability in the coating may occur, is that the not less than 60% by weight of the coating is too flexible prevent forming the appropriate coating do.
- the coating part it is possible to obtain an encapsulated drug particle by spraying a coating agent while flowing the active ingredient.
- the encapsulated drug particle is formed by granulating the coating agent by powder coating the outer surface of the active ingredient on a fluidized bed. You can get it.
- the particles also include granules.
- the content of the coating agent including a sugar or derivative thereof and a plasticizer formed outside the drug moiety is 10 to 100 based on 100 parts by weight of the active ingredient.
- the coating part is a weight part. If the coating part is less than 10 parts by weight based on 100 parts by weight of the active ingredient, the stability of the active ingredient may be lowered. When the coating part is more than 100 parts by weight, the size of the preparation may be increased and the oral dose may be reduced.
- sustained-release pharmaceutical composition of the present invention comprises a drug release control unit (c) comprising a pharmaceutically acceptable sustained-release excipient.
- the sustained release excipient includes a matrix forming agent, such a matrix
- the forming agent is hydroxypropyl methyl cellulose (HPMC), hydroxyethyl methyl cellulose (Hydroxyethyl methyl cellulose),
- Hydroxymethyl cellulose (Hydroxymethyl cellulose),
- Hydroxyethyl cellulose (Hydroxyethyl cellulose),
- Carboxymethyl cellulose Carboxymethyl cellulose, Carboxymethyl cellulose, Calcium Carboxymethyl cellulose, Sodium Carboxymethyl cellulose, Methylcellulose, Methylcellulose, Ethylcellulose, Polyethylene oxide, Locust bean gum, Guar gum, Xanthan gum, Acacia gum, Tragacanth gum, Alginic acid , Sodium alginate, calcium alginate, ammonium alginate, agar, gelatin, poloxamer, polymethacrylate, carbomer ), Polyvinylpyrrolidone (PVP; Polyvinyl pyrrolidone), polyvinyl alcohol, polyvinyl acetate (PVAc; Polyvinyl acetate), polyethylene glycol,
- Silicate Magnetic aluminum silicate
- Polydextrose Polydextrose
- At least one swelling agent selected from the group consisting of hydroxypropylmethylcellulose, polyethylene oxide, carbomer and poloxamer.
- the matrix forming agent may include a gas generator together with the swelling agent.
- gas generators include sodium carbonate or Sodium bicarbonate, but may be used without limitation as long as it is used in the art. Preferably, sodium bicarbonate is used.
- the sustained release excipient may further include other pharmaceutically acceptable additives in addition to the matrix forming agent to enhance drug release of the sustained release form of the active ingredient.
- the additives include binders, lubricants, stabilizers, surfactants, solubilizers, sweeteners, copulating agents, flavoring agents, pigments, wetting agents, layering agents, thickeners, ⁇ regulators, disintegrants, and the like.
- the present invention is not limited thereto, and any pharmaceutically acceptable agent may be used.
- the components of the pharmaceutical composition are generally subjected to the processes of association, granulation, drying, formulation, spray coating, mixing, lubrication, tableting, layering and coating.
- Oral dosage unit formulations are typically obtained by compression molding (tablets), layered (capsules), mixed (fine granules, dry syrup).
- the components can be combined and managed during the process.
- the active ingredient may be mixed with the remaining ingredients after granulating with one or more ingredients, for example by granulation, fluidized bed or extrusion granulation.
- the active ingredient is first granulated with the components constituting one or more matrix formers, and other excipients such as swelling agents, gelling agents, diluents, lubricants and the like may subsequently be combined in one or more blending operations.
- the compressed dosage form can be subjected to further processing such as polishing, coating, and the like.
- the sustained-release excipient included in the drug release control unit to prepare a matrix forming agent by mixing the swelling agent and the gas generator, and further pharmaceutically acceptable It may be prepared by a method of adding other additives.
- the swelling agent, the gas generator and the pharmaceutically acceptable other additives according to the method of simple mixing Sustained release excipients may be prepared, but in order to ensure excellent stability of pregabalin, other pharmaceutically acceptable additives or the other additives and
- the sustained-release excipient After granulating the gas generating agent, it is preferable to prepare the sustained-release excipient by post-mixing the prepared granules with the swelling agent. In other words, it is preferable that the granules do not include a swelling agent. In the formulation molding process, such as tableting for the formulation of a sustained release composition according to the present invention, the formulation is not properly formed.
- Drug release control portion may be included in the overall composition compared to an amount of about 10 parts by weight 0 /. To about 50 weight 0/0, preferably from about 15% to about 40% by weight.
- the content of the drug release control portion is less than 15% by weight can not exhibit a sustained sustained release effect, if it exceeds 40 weight 0 /. It does not release the active ingredient in the formulation can not exhibit the desired pharmacological effect.
- Pregabalin-containing sustained-release pharmaceutical composition of the present invention in addition to the configuration of the above (a) (b) (c), for the purpose of improving the preparation of the formulation, compressibility, appearance and preferences, etc. It may further comprise an excipient.
- stabilizers for example, stabilizers, surfactants, lubricants, solubilizers, loosening agents, sweeteners, adsorbents, copulating agents, binders, suspending agents, curing agents, antioxidants, varnishes, flavoring agents, flavoring agents, pigments, coating agents, wetting agents, Wetting modifiers, layering agents, defoamers, coolants, chewing agents, antistatic agents, coloring agents, dragees, isotonic agents, emollients, emulsifiers, tackifiers, thickeners, blowing agents, ⁇ regulators, excipients, dispersants, disintegrants, waterproofing agents, preservatives, Preservatives, dissolution aids, solvents, glidants and the like may be added as necessary.
- the sustained release pharmaceutical composition of the present invention may further include a diluent, a binder, a disintegrant or a lubricant.
- the diluent may include lactose, cellulose, microcrystalline cellulose, starch, etc.
- lactose includes lactose monohydrate, lactose anhydride, spray dried lactose monohydrate, and the like.
- Microcrystalline cells include microcrystalline cells, silicate microcrystalline cells, and the like, and starch may include corn starch, pregelatinized starch, and the like, but is not limited thereto.
- polyvinyl alcohol polyvinyl alcohol,-polyethylene glycol graft copolymer, polyvinylpyridone vinyl acetate, ethyl cellulose, hydroxypropyl cellulose, Hydroxypropylmethyl cellulose, carboxymethyl cellulose, methyl cellulose, polyvinyl alcohol, polyvinylpyridone, polyacrylic acid, gelatin, propylene glycol, sodium alginate, and the like, but are not limited thereto. .
- the disintegrants include starch, cellulose, crosslinked polymers such as crosslinked polyvinylpyrrolidone or crospovidone, such as POLYPLASDONE XL manufactured by International Specialty Products (USA); Cross-linked sodium carboxymethylcellose or croscarmellose sodium, for example AC-DI-SOL from FMC; And crosslinked calcium carboxymethyl cellulose, but are not limited thereto.
- the lubricant may include, but is not limited to, magnesium stearate, sodium stearyl fumarate, glyceryl behenate, and the like.
- the present invention may include a small amount of a pharmaceutically acceptable film coating.
- the film coating is hydroxypropyl methyl cellulose (HPMC),
- HPC Hydroxypropyl cellulose
- HEC hydroxyethyl cellulose
- CAP Cellulose acetate phthalate
- EC ethyl cellulose
- MC methyl cellulose
- polymethacrylate polyvinyl alcohol-polyethylene glycol graft
- Polyvinyl alcohol (PVA) (Opadry®; Colorcon, USA) and combinations thereof may be used, but is not limited thereto.
- Sustained release formulations comprising the sustained release composition of the present invention are not particularly limited as long as they are oral formulations, and may be, for example, formulated in the form of tablets, capsules, granules, granules, or pellets. And it can be used for the treatment of various mental disorders such as neuropathic pain, epilepsy, fibromyalgia.
- sustained release formulation administration of the invention may be selected by the attending physician depending on the characteristics of the patient, in particular age, weight, lifestyle, level of symptoms and case.
- the sustained release formulation of the present invention may be used to determine the concentration of the active ingredient in plasma.
- It may be provided in a form suitable for once-a-day dosing to keep constant and reduce the number of dosing subjects to be able to follow.
- the sustained release pharmaceutical composition may be eluted for a long time in a sustained release form in a sustained release form at a desired drug absorption position, and therefore, at least 12 hours, preferably 18 hours after oral administration. , More Preferably it is characterized by lasting for 24 hours.
- the sustained release formulation of the present invention is pre-eluted slowly for effective once daily ⁇ taking all of the valine can be seen that represents the dissolution rate of 100% after about 24 hours.
- the sustained-release pharmaceutical composition of the present invention dissolution rate under long-term storage conditions (25 ° C, 60% relative humidity), accelerated conditions (40 ° C, 75% relative humidity), harsh conditions (60 ° C, airtight container) It is characterized in that the stability is maintained without a great change. Therefore, the composition of the present invention has an excellent effect in terms of ease of taking and formulation stability.
- the present invention relates to a method for preparing a sustained release pharmaceutical composition containing the pregabalin or a salt thereof.
- the step of forming the drug coating may be carried out by coating the coating on the drug portion in accordance with conventional methods known in the pharmaceutical art.
- the coating agent may be sprayed while flowing the active ingredient to obtain the coated drug particles, and more preferably, the coated drug may be granulated to coat the outer surface of the active ingredient on the fluidized bed to obtain stabilized drug particles. have.
- sustained-release pharmaceutical composition prepared as described above may be prepared in a final formulation according to a conventional formulation method, for example, a conventional tablet or capsul preparation method.
- a coating containing the active ingredient (pregabalin) was prepared by completely dissolving 56 mg and 24 mg of colicoat eye in water. Pregabalin coatings were obtained by powder coating the coating on 300 mg of pregabalin.
- a fluidized bed coater (Glatt GPCG2 Labsystem, Germany) was used for powder coating of pregabalin. It was operated under the conditions of temperature 65 ° C, product temperature 30 ° C, spray rate 1.34mL / min, spray nozzle pressure l .Sbar, spray nozzle diameter 0.8mm. Table 1 shows the operating conditions of the fluidized bed coater.
- the contrast weight coated portion includes a main component and 14.7 parts by weight 0/0 manni in conjunction with the Kollicoat ahyial 24g 56g purified water l, completely dissolved in 176g
- the coating part containing the main component is manufactured by spraying the coating agent.
- the coating portion formed after ' are shown in Table 4 above.
- Examples 1-1 to 1-4 Preparation of sustained-release composition containing pregabalin (1) According to the composition shown in Table 5 below, a sustained-release composition containing pregabalin as an active ingredient was prepared. Specifically, first, according to the method described in Preparation Example 1-1 for the preparation of the coating portion containing the active ingredient, the weight percent of each component was varied according to Table 5 below.
- the coating part including the active ingredient thus prepared was mixed with the components of the mixing part of Table 5 below at 20 rpm in V-Mixer (V-mixerl20L of Dasan Pharmatech Co., Ltd.) for 10 minutes. Magnesium stearate was added to the obtained mixture
- V-Mixer V-mixerl20L from Dasan Pharmatech Co., Ltd.
- the final mixture was prepared.
- the tablets were molded into tablets with a hardness of 10-15 Kp using a tablet press (Kikusui's Hercules2) to prepare uncoated tablets according to the present invention.
- the dissolution test was conducted by the 10th Amendment Dissolution Test Method. 0.06N-HCL hydrochloride buffer was used as the eluent. The elution was performed using paddle method, the eluent was 900 mL, the stirring speed was 50 rpm, the elution temperature was 37 ⁇ 0.5 ° C, and the saccharin was used.
- 5 ml of samples were taken at 0, 1.0, 2.0, 4.0, 6.0, 7.0, 8.0, 10.0, 12.0, 14.0, 16.0, 18.0, 20.0, and 24.0 hours.
- 5 ml of the sample was taken at 0,0.5, 1.0,4.0,6.0, 12.0,24.0 hours
- 0,0.5, 1.0,2.0 5 ml of the sample was taken at 4.0,6.0, 10.0, and 12.0 hours
- 5 ml of the sample was taken at 0, 1.0, 2.0, 4.0, 6.0, and 10.0 hours for Examples 2-1 to 2-3.
- Analytical conditions are 0.45 from the above dissolution test.
- the dissolution graph of FIG. 2 was also evaluated by the dissolution test and analysis method using the eight tablets of Example 2-2.
- the dissolution rate was examined through sample samples of 0, 1.0, 2.0, 4.0, 6.0, 7.0, 8.0, 10.0, 12.0, 14.0, 16.0, 18.0, 20.0, and 24.0 hours.
- Example 1-1 Example 1-2
- Example 1-3 Example 1-4
- the swelling rate of the tablet containing the composite swellable polymer together with the active ingredient pregabalin was confirmed. Specifically, the same ratio of collidone shown in Table 10 below SR and Plasdon XL, Polyox, HEC, and HPMC were added to confirm the expansion rate of the composite swellable tablets of the tablet containing the main component.
- Comparative Example 3-1 shows an appropriate size that does not pass the above sentence by the manufacturing method disclosed in Korean Patent Publication No. 2008-0059427 (Pfizer).
- the expansion ratios of Examples 3-2 to 3-4 were confirmed by photographs in Table 1, and the specific sizes were confirmed by checking the length, shortening, and thickness in Table 12.
- 900 mL of 0.06N-HCL complete layer solution as eluent The paddle method was used as the elution method.
- the stirring speed was 50 rpm, the elution degree was 4 hours at 37 ⁇ 0.5 ° C. 15).
- Example 3-2 Example 3-3 ⁇ Example 3-4 ⁇
- Example 2-1 5-7 5-7 Example 2-2 5-7 5-7
- Pregabalin lg and each of the excipients listed in Table 14 were combined at room temperature, ligated in glass vials in powder form, and stored in vials for 2 weeks in harsh conditions (60 ° C.), then through HPLC. Lactone analog (PRG-Lactam) was expressed in terms of 0 /.
- the mobile phase A was maintained at 70% and the mobile phase B was 30%, and the post time was set at 10 minutes.
- Flow rate is adjusted so that the pregabalin holding time is about 8 minutes (0.9
- the column was a octadecylsilyl silica gel for liquid chromatography of 5 in a stainless steel pipe having an inner diameter of about 4.6 mm and a length of about 250 mm. The results are shown in Table 14 below. .
- pregabalin In order to confirm the stability of pregabalin when sucrose was coated as a saccharide and added an excipient to pregabalin, 300 g of pregabalin was prepared in the same manner as in the production conditions of the coating part described in Production Example 1-1. Prepared according to the preparation of the coating of -2. Thereafter, each of the excipients described in Table 15 was 1: 1 physically mixed with the prepared sucrose-coated pregabalin, and then stored for 2 weeks in harsh conditions by the same method as in Experimental Example 4 (1). The test results are shown in Table 15 below.
- pregabalin In order to confirm the stability of pregabalin when manganese was coated as a sugar to pregabalin and an excipient was added, 300 g of pregabalin was prepared in the same manner as in the production conditions of the coating part described in Production Example 1-1. It was prepared according to the preparation of the coating part 1-3. Thereafter, each of the excipients shown in Table 16 was 1: 1 physically mixed with the prepared Manni-coated pregabalin by weight, and then stored for 2 weeks in harsh conditions by the same method as in Experimental Example 4 (1). The test results are shown in Table 16 below.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/129,584 US20170172929A1 (en) | 2014-04-07 | 2015-04-07 | Pharmaceutical composition containing pregabalin with improved stability and method for preparing same |
CN201580019143.XA CN106163566A (zh) | 2014-04-07 | 2015-04-07 | 稳定性提高的含普瑞巴林的药物组合物及其制备方法 |
EP15776615.5A EP3130355A4 (en) | 2014-04-07 | 2015-04-07 | Pharmaceutical composition containing pregabalin with improved stability and method for preparing same |
JP2016561374A JP2017510599A (ja) | 2014-04-07 | 2015-04-07 | 安定性が改善されたプレガバリンを含有する薬剤学的組成物およびその製造方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020140041321A KR102221846B1 (ko) | 2014-04-07 | 2014-04-07 | 안정성이 개선된 프레가발린을 함유하는 약제학적 조성물 및 이의 제조방법 |
KR10-2014-0041321 | 2014-04-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015156581A1 true WO2015156581A1 (ko) | 2015-10-15 |
Family
ID=54288094
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2015/003475 WO2015156581A1 (ko) | 2014-04-07 | 2015-04-07 | 안정성이 개선된 프레가발린을 함유하는 약제학적 조성물 및 이의 제조방법 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20170172929A1 (ko) |
EP (1) | EP3130355A4 (ko) |
JP (1) | JP2017510599A (ko) |
KR (1) | KR102221846B1 (ko) |
CN (1) | CN106163566A (ko) |
WO (1) | WO2015156581A1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019507101A (ja) * | 2017-02-01 | 2019-03-14 | ジーエル・ファームテック・コーポレイション | 含プレガバリン経口用徐放性三重錠剤 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102072546B1 (ko) | 2016-10-14 | 2020-02-04 | 주식회사 삼양바이오팜 | 레날리도마이드의 경구용 정제 조성물 |
JP2019142834A (ja) * | 2017-07-31 | 2019-08-29 | 大原薬品工業株式会社 | プレガバリン並びに好適な賦形剤を含有する固形製剤 |
CN108159011A (zh) * | 2018-03-16 | 2018-06-15 | 中国药科大学 | 一种双相控释的普瑞巴林胃滞留缓释片及其制备方法 |
WO2019238068A1 (zh) | 2018-06-13 | 2019-12-19 | 北京泰德制药股份有限公司 | 一种普瑞巴林缓释组合物及其制备方法 |
CN111053749B (zh) * | 2018-10-16 | 2022-07-15 | 北京泰德制药股份有限公司 | 一种普瑞巴林缓释组合物及其制备方法 |
CN113577036B (zh) * | 2021-05-31 | 2023-04-04 | 石药集团欧意药业有限公司 | 一种普瑞巴林胃漂浮缓释片及其制备方法 |
CN113616591B (zh) * | 2021-09-03 | 2023-05-23 | 贝克诺顿(浙江)制药有限公司 | 一种普瑞巴林口服溶液及制备方法 |
CN114246836B (zh) * | 2022-01-21 | 2023-07-07 | 杭州新诺华医药有限公司 | 一种普瑞巴林缓释片及其制备方法 |
GB2624861A (en) * | 2022-11-28 | 2024-06-05 | Orbit Pharma Ltd | Sustained release pharmaceutical compositions comprising pregabalin or pharmaceutically acceptable salts thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5759577A (en) * | 1995-01-17 | 1998-06-02 | American Home Products Corporation | Controlled release of steroids from sugar coatings |
US20020012679A1 (en) * | 1998-08-03 | 2002-01-31 | Societe Laboratoires Des Produits Ethiques - Ethypharm | Process for manufacturing coated gabapentin or pregabalin particles |
US20050142195A1 (en) * | 2002-11-21 | 2005-06-30 | Boyong Li | Stable pharmaceutical compositions without a stabilizer |
US20100255067A1 (en) * | 2007-11-23 | 2010-10-07 | Lupin Limited | Controlled Release Pharmaceutical Compositions of Pregabalin |
KR20130023127A (ko) * | 2011-08-26 | 2013-03-07 | 근화제약주식회사 | 프레가발린을 포함하는 서방성 제제 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2006206423A1 (en) * | 2005-01-21 | 2006-07-27 | Pharmanova Inc. | Pharmaceutical formulations and methods of use |
NL2000281C2 (nl) * | 2005-11-02 | 2007-08-07 | Pfizer Prod Inc | Vaste farmaceutische samenstellingen die pregabaline bevatten. |
US20080014257A1 (en) * | 2006-07-14 | 2008-01-17 | Par Pharmaceutical, Inc. | Oral dosage forms |
EP2440190A1 (en) * | 2009-06-12 | 2012-04-18 | Micro Labs Limited | Novel pharmaceutical compositions containing pregabalin |
KR101317592B1 (ko) * | 2009-10-28 | 2013-10-15 | 씨제이제일제당 (주) | 프레가발린, 폴리에틸렌옥사이드 및 폴리비닐알코올-폴리에틸렌글리콜 그라프트 공중합체를 함유하는 위체류형 서방성 제제 |
KR101648490B1 (ko) * | 2009-11-02 | 2016-08-17 | 한미사이언스 주식회사 | 위체류 약물 전달시스템을 이용한 서방성 경구용 제제 |
US20130078290A1 (en) * | 2010-06-01 | 2013-03-28 | Rubicon Research Private Limited | Gastroretentive Dosage Forms Of GABA Analogs |
WO2012035559A2 (en) * | 2010-09-17 | 2012-03-22 | Panacea Biotec Ltd | Sustained release pharmaceutical compositions comprising pregabalin |
EP2736499B1 (en) * | 2011-07-26 | 2016-05-11 | Yuhan Corporation | Sustained release tablet comprising pregabalin through two-phase release-controlling system |
IN2014DN06965A (ko) * | 2012-01-30 | 2015-04-10 | Ranbaxy Lab Ltd | |
CN103271888A (zh) * | 2013-06-18 | 2013-09-04 | 上海奥科达生物医药科技有限公司 | 普瑞巴林口崩片和分散片及其制备方法 |
-
2014
- 2014-04-07 KR KR1020140041321A patent/KR102221846B1/ko active IP Right Grant
-
2015
- 2015-04-07 US US15/129,584 patent/US20170172929A1/en not_active Abandoned
- 2015-04-07 JP JP2016561374A patent/JP2017510599A/ja active Pending
- 2015-04-07 WO PCT/KR2015/003475 patent/WO2015156581A1/ko active Application Filing
- 2015-04-07 EP EP15776615.5A patent/EP3130355A4/en not_active Withdrawn
- 2015-04-07 CN CN201580019143.XA patent/CN106163566A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5759577A (en) * | 1995-01-17 | 1998-06-02 | American Home Products Corporation | Controlled release of steroids from sugar coatings |
US20020012679A1 (en) * | 1998-08-03 | 2002-01-31 | Societe Laboratoires Des Produits Ethiques - Ethypharm | Process for manufacturing coated gabapentin or pregabalin particles |
US20050142195A1 (en) * | 2002-11-21 | 2005-06-30 | Boyong Li | Stable pharmaceutical compositions without a stabilizer |
US20100255067A1 (en) * | 2007-11-23 | 2010-10-07 | Lupin Limited | Controlled Release Pharmaceutical Compositions of Pregabalin |
KR20130023127A (ko) * | 2011-08-26 | 2013-03-07 | 근화제약주식회사 | 프레가발린을 포함하는 서방성 제제 |
Non-Patent Citations (1)
Title |
---|
See also references of EP3130355A4 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019507101A (ja) * | 2017-02-01 | 2019-03-14 | ジーエル・ファームテック・コーポレイション | 含プレガバリン経口用徐放性三重錠剤 |
Also Published As
Publication number | Publication date |
---|---|
CN106163566A (zh) | 2016-11-23 |
KR102221846B1 (ko) | 2021-02-26 |
JP2017510599A (ja) | 2017-04-13 |
EP3130355A4 (en) | 2017-12-20 |
KR20150116280A (ko) | 2015-10-15 |
EP3130355A1 (en) | 2017-02-15 |
US20170172929A1 (en) | 2017-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2015156581A1 (ko) | 안정성이 개선된 프레가발린을 함유하는 약제학적 조성물 및 이의 제조방법 | |
KR101699912B1 (ko) | 1종 이상의 푸마르산 에스테르를 침식 매트릭스에 함유하는 제제 | |
US20140186450A1 (en) | Gastroresistant pharmaceutical formulations containing rifaximin | |
WO2011111818A1 (ja) | モサプリドまたはその塩を含む徐放型医薬組成物 | |
JP2010532746A (ja) | 放出調節医薬組成物およびその製造方法 | |
HU231114B1 (hu) | Mikofenolsavat vagy mikofenolátot tartalmazó gyógyszerkészítmények | |
KR20110046360A (ko) | 프레가발린, 폴리에틸렌옥사이드 및 폴리비닐알코올-폴리에틸렌글리콜 그라프트 공중합체를 함유하는 위체류형 서방성 제제 | |
KR100591142B1 (ko) | 파록세틴을 활성물질로 함유하는 장용성 서방형 정제 | |
CA2697437A1 (en) | Pharmaceutical combination of aliskiren and valsartan | |
JP2008534681A (ja) | ジピリダモール持続放出製剤及びそれを調製のための方法 | |
GB2414668A (en) | Sustained release delivery system for tetracycline compounds | |
EP2391345B1 (en) | Galenic formulations comprising aliskiren | |
WO2010026467A2 (en) | Controlled release dosage form of high solubility active ingredient | |
WO2017208136A1 (en) | Pharmaceutical composition of dapagliflozin co-crystal | |
WO2011051967A2 (en) | Pharmaceutical compositions comprising mycophenolate and processes for preparing thereof | |
WO2010044097A2 (en) | Novel dosage form of paliperidone and process for preparing the same | |
KR100762846B1 (ko) | 서방성 제제 | |
EP3796908B1 (en) | Controlled release propiverine formulations | |
WO2013032185A1 (ko) | 프레가발린을 포함하는 서방성 제제 | |
KR20200078146A (ko) | 내산성이 우수한 탐수로신 염산염 함유 제약 조성물 및 이의 제조방법 | |
WO2002066004A1 (fr) | Compositions a liberation controlee de medicament | |
JP2009525953A (ja) | ジバルプロ酸及びその誘導体の徐放性製剤 | |
WO2013054178A2 (en) | Extended release pharmaceutical compositions containing carmabazepine | |
AU2020282348A1 (en) | Modified release formulation of a pyrimidinylamino-pyrazole compound, and methods of treatment | |
JP2016538315A (ja) | アセブロフィリン及び親水性徐放性基剤を含む徐放性薬学組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15776615 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15129584 Country of ref document: US |
|
REEP | Request for entry into the european phase |
Ref document number: 2015776615 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2015776615 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2016561374 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |